← All trials
NCT04094727
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2019
- Primary completion
- May 31, 2020
- Completion date
- May 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 3500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- University of LondonCollaborator
- University of California, San FranciscoOverall official - principal investigator
- The University of Texas, DallasCollaborator
- University of Notre Dame AustraliaCollaborator
- University of NamibiaCollaborator
- Government of NamibiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.